A Comprehensive Review of MEDVi’s Personalized GLP-1 Weight Loss Solutions Featuring Affordable Compounded Semaglutide and ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...

Houston-based Empower Pharmacy has repeatedly been admonished by the FDA for failing to follow federal rules that ensure drug ...

Research presented at the the European Congress on Obesity suggests weight loss injections are safe and work for the mentally ...

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Mounjaro has been found to be more effective than Wegovy in the first direct comparison trial of two major weight-loss drugs. Both medications led to substantial weight loss, but those who took ...

The first head-to-head trial of obesity drugs reveals a clear winner for effective weight loss. But how does it work, and what are the long-term effects? Anna Magee reports ...

If approved, oral semaglutide 25-milligram is expected to be the first oral GLP-1 receptor agonist for weight loss. The manufacturing of the active pharmaceutical ingredient, bulk tablet ...

Pharmaceutical company Novo Nordisk (NVO) came out swinging Wednesday morning as the stock initially jumped on its first quarter earnings beat ($0.99 per share vs. estimates of $0.94). Revenue figures ...

"This study gives us confidence that people who are resistant or reluctant to take injections can still have an option for clinical benefit with [semaglutide] in the form of a tablet." It has also ...